Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma

The immune checkpoint inhibitors used for adjuvant therapy after surgery were consistent with those used during the neoadjuvant treatment before surgery, including pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab.

Postoperative observation is conducted without the use of any anti-tumor treatment.